Britain and America have established a major bilateral deal that will keep zero tariffs on UK medicine products entering the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on medicines through the NHS. This move ensures that import taxes on these key goods will remain at nothing for a period of three years.
This agreement comes after earlier statements to significantly raise import taxes on patented drug products, with potential rates discussed reaching 100%.
"This arrangement with the UK bolsters the global environment for new treatments and brings long-overdue equity to American-British medicine commerce," a release said.
Commercial Significance
Medicines represent one of the Britain's largest exports to the America, which is clearly the biggest destination for large companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period to the end of September, the UK shipped medicines worth billions to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This guarantee safeguards work, increases funding and facilitates the UK to emerge as a global hub for medical research," a minister stated.
Detailed British Pledges
The pact involves several key changes from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to double overall health service expenditure on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. Last year, rebates topped 20%.
Recent Tensions
The deal takes place against a long-running row between the sector and the British authorities over drug pricing and approval rates.
These tensions were intensified by assertions that American customers were charged a premium for the same drugs than people in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or cancelled, while substantial funding commitments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
